Roger Smith - T2 Biosystms Senior Development
| TTOO Stock | USD 0.51 0.08 18.60% |
Executive
Roger Smith is Senior Development of T2 Biosystms
| Age | 59 |
| Address | 101 Hartwell Avenue, Lexington, MA, United States, 02421 |
| Phone | 781 761 4646 |
| Web | https://www.t2biosystems.com |
Roger Smith Latest Insider Activity
Tracking and analyzing the buying and selling activities of Roger Smith against T2 Biosystms stock is an integral part of due diligence when investing in T2 Biosystms. Roger Smith insider activity provides valuable insight into whether T2 Biosystms is net buyers or sellers over its current business cycle. Note, T2 Biosystms insiders must abide by specific rules, including filing SEC forms every time they buy or sell T2 Biosystms'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Roger Smith over two months ago Disposition of 228119 shares by Roger Smith of Ur Energy at 0.5824 subject to Rule 16b-3 | ||
Roger Smith over six months ago Acquisition by Roger Smith of 109536 shares of Ur Energy subject to Rule 16b-3 | ||
Roger Smith over a year ago Exercise or conversion by Roger Smith of 74067 shares of Ur Energy subject to Rule 16b-3 | ||
Roger Smith over a year ago Exercise or conversion by Roger Smith of 18442 shares of Ur Energy subject to Rule 16b-3 |
T2 Biosystms Management Efficiency
The company has return on total asset (ROA) of (0.9046) % which means that it has lost $0.9046 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (6.2214) %, meaning that it created substantial loss on money invested by shareholders. T2 Biosystms' management efficiency ratios could be used to measure how well T2 Biosystms manages its routine affairs as well as how well it operates its assets and liabilities. At this time, T2 Biosystms' Return On Capital Employed is very stable compared to the past year. As of the 22nd of November 2024, Return On Equity is likely to grow to 1.88, while Return On Tangible Assets are likely to drop (1.51). At this time, T2 Biosystms' Total Assets are very stable compared to the past year. As of the 22nd of November 2024, Non Current Assets Total is likely to grow to about 11.6 M, while Non Currrent Assets Other are likely to drop about 345.7 K.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Bas Verhoef | Illumina | N/A | |
| Robert III | Waters | N/A | |
| CPA BCom | Genetic Technologies | 57 | |
| Karen Nelson | Thermo Fisher Scientific | N/A | |
| James Polewaczyk | IDEXX Laboratories | 60 | |
| Joydeep MBA | Illumina | 53 | |
| Kathryne Reeves | Illumina | 55 | |
| Victoria Gavrilenko | Intelligent Bio Solutions | 41 | |
| Dallas Coleman | bioAffinity Technologies, | N/A | |
| Daniel JD | Danaher | 57 | |
| Leslie Hoyt | iSpecimen | N/A | |
| Steven Hoffman | Illumina | N/A | |
| Rafael Tejada | Thermo Fisher Scientific | N/A | |
| George Fennell | IDEXX Laboratories | 55 | |
| Jenny Zheng | Illumina | N/A | |
| John Bedford | Danaher | N/A | |
| Ankur CPA | Illumina | 48 | |
| Carly Lejnieks | iSpecimen | N/A | |
| Christos Ross | Waters | N/A | |
| Scott Davies | Illumina | N/A | |
| Annette Arnold | iSpecimen | N/A | |
Management Performance
| Return On Equity | -6.22 | ||||
| Return On Asset | -0.9 |
T2 Biosystms Leadership Team
Elected by the shareholders, the T2 Biosystms' board of directors comprises two types of representatives: T2 Biosystms inside directors who are chosen from within the company, and outside directors, selected externally and held independent of TTOO. The board's role is to monitor T2 Biosystms' management team and ensure that shareholders' interests are well served. T2 Biosystms' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, T2 Biosystms' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Roger Smith, Senior Development | ||
| Aparna MD, Chief Board | ||
| Kelley Morgan, Chief Officer | ||
| BSc III, CEO President | ||
| Michael Esq, Sr Counsel | ||
| Brett Giffin, Chief Officer | ||
| Alec Barclay, Senior Vice President - Operations | ||
| John CPA, Chief Officer |
TTOO Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is T2 Biosystms a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -6.22 | ||||
| Return On Asset | -0.9 | ||||
| Operating Margin | (4.91) % | ||||
| Current Valuation | 25.82 M | ||||
| Shares Outstanding | 21.04 M | ||||
| Shares Owned By Insiders | 10.17 % | ||||
| Shares Owned By Institutions | 73.51 % | ||||
| Number Of Shares Shorted | 834.76 K | ||||
| Price To Earning | (2.04) X | ||||
| Price To Book | 14.50 X |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in T2 Biosystms. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. To learn how to invest in TTOO Stock, please use our How to Invest in T2 Biosystms guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of T2 Biosystms. If investors know TTOO will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about T2 Biosystms listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.03) | Revenue Per Share 0.999 | Quarterly Revenue Growth (0.01) | Return On Assets (0.90) | Return On Equity (6.22) |
The market value of T2 Biosystms is measured differently than its book value, which is the value of TTOO that is recorded on the company's balance sheet. Investors also form their own opinion of T2 Biosystms' value that differs from its market value or its book value, called intrinsic value, which is T2 Biosystms' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because T2 Biosystms' market value can be influenced by many factors that don't directly affect T2 Biosystms' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between T2 Biosystms' value and its price as these two are different measures arrived at by different means. Investors typically determine if T2 Biosystms is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, T2 Biosystms' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.